Arrowhead Research (ARWR) to Eliminate Chief Scientific Officer Position

December 1, 2016 4:58 PM EST

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Arrowhead Research (NASDAQ: ARWR) notified David Lewis, the Company’s Chief Scientific Officer, that his position will be terminated, effective December 13, 2016.

This follows recent news that the company will be discontinuing development of its clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCivTM, or EX1, delivery vehicle and redeploying its resources to support the development of RNAi therapeutics that utilize the Company’s proprietary subcutaneous and extra-hepatic delivery systems.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Changes

Add Your Comment